Want to see ISPC full AI Analyst Report?
ISPC Stock Chart & Stats
$0.31
-$0.03(-1.03%)
At close: 4:00 PM EST
$0.31
-$0.03(-1.03%)
Day’s Range― - ―
52-Week Range$1.77 - $127.20
Previous CloseN/A
Volume25.67K
Average Volume (3M)8.88M
Market Cap
$5.67M
Enterprise Value$5.03
Total Cash (Recent Filing)$4.41M
Total Debt (Recent Filing)$240.90K
Price to Earnings (P/E)―
Beta1.47
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding2,518,590
10 Day Avg. Volume698,577
30 Day Avg. Volume8,882,166
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.39
Price to Sales (P/S)0.62
P/FCF Ratio-0.28
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Financial LeverageModest debt reduces interest and refinancing pressure while the company works to improve operations. This provides more balance-sheet flexibility than a highly leveraged structure, although losses remain a significant constraint.
Access To Growth CapitalThe financing gives iSpecimen additional liquidity for liabilities, working capital, marketing, and potential acquisitions or technology investments. Access to equity capital can support continuity and strategic execution, despite dilution risk.
Marketplace Technology ExpansionA more capable and connected digital marketplace can improve supplier participation, customer access, and operating scalability. Broader integrations may strengthen the platform’s role in coordinating compliant biospecimen sourcing over time.
Bears Say
Severe Revenue And Margin DeteriorationSharp revenue contraction combined with negative gross profit indicates that the core service is not currently covering its delivery economics. Sustained losses would limit reinvestment capacity and make recovery dependent on restoring demand and margins.
Persistent Cash Burn And Equity ErosionThe business is consuming substantial cash rather than funding itself, while cumulative losses have materially reduced the capital base. Continued burn could require repeated financing, increasing dilution risk and weakening financial resilience.
Nasdaq Listing Compliance RiskFailure to regain the required equity level could jeopardize continued Nasdaq listing and reduce access to public-market financing. The issue also signals limited balance-sheet capacity and may distract management from rebuilding the operating business.
iSpecimen News
ISPC FAQ
What was iSpecimen’s price range in the past 12 months?
iSpecimen lowest stock price was $1.77 and its highest was $127.20 in the past 12 months.
What is iSpecimen’s market cap?
iSpecimen’s market cap is $5.67M.
When is iSpecimen’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were iSpecimen’s earnings last quarter?
Currently, no data Available
Is iSpecimen overvalued?
According to Wall Street analysts iSpecimen’s price is currently Overvalued.
Does iSpecimen pay dividends?
iSpecimen does not currently pay dividends.
What is iSpecimen’s EPS estimate?
iSpecimen’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does iSpecimen have?
iSpecimen has 2,518,590 shares outstanding.
What happened to iSpecimen’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of iSpecimen?
Currently, no hedge funds are holding shares in ISPC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
iSpecimen
iSpecimen Inc. operates a sophisticated technological platform that effectively bridges the gap between life science researchers and crucial human biological materials. Its proprietary cloud-based system empowers scientists to efficiently locate and access a vast array of biospecimens—such as biofluids, tissues, and living cells—as well as connect with potential study subjects, all sourced from a global network of healthcare providers, including hospitals, laboratories, biobanks, and blood centers. The company develops and manages iSpecimen Marketplace, an innovative online hub that strategically links medical researchers requiring access to subjects, samples, and pertinent data with organizations that hold these invaluable resources. iSpecimen's clientele primarily includes biopharmaceutical firms, in vitro diagnostics companies, and governmental and academic research institutions. The company, established in 2009, is headquartered in Lexington, Massachusetts.
Technical Analysis
―
Intelligent Bio Solutions
―
BioNexus Gene Lab Corp
―
―
bioAffinity Technologies, Inc.
―
Ownership Overview
―
Insiders
2.52% Mutual Funds
― Other Institutional Investors
97.48% Public Companies and
Individual Investors